Epilepsy service provision in the National Health Service in England in 2012.

Seizure

Academic Neurology Unit, University of Sheffield, Royal Hallamshire Hospital, Glossop Road S10 2JF, United Kingdom. Electronic address:

Published: August 2015

Purpose: The National Health Service in the United Kingdom compares favourably on many international measures of quality and cost-effectiveness. It has many centres of excellence for epilepsy care and in some areas is a world-leader. However, for over twenty years there have been concerns that the provision of good quality care is variable and in many areas major improvements are required. We report the results of the latest major survey into the quality of epilepsy care in the NHS.

Methods: Four target groups were sent questionnaires: acute hospital trusts, Clinical Commissioning Groups, local authorities and patients. Each questionnaire was specifically designed by Epilepsy Action after reviewing national guidance and quality standards.

Results: We present the key results of the survey and we discuss them in the context of the latest national guidelines, quality standards, the organisational structure of the NHS and the research literature.

Conclusion: Although there are some examples of excellent services for people with epilepsy these results show that overall there has been little improvement in recent years and there continues to be significant geographical variability in quality with many areas offering sub-optimal care.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.seizure.2015.05.009DOI Listing

Publication Analysis

Top Keywords

national health
8
health service
8
epilepsy care
8
quality
6
epilepsy
5
epilepsy service
4
service provision
4
national
4
provision national
4
service england
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.

Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Bioengineering, University of California, Los Angeles, CA, USA, Los Angeles, CA, USA.

Background: The initiation of amyloid plaque deposition signifies a crucial stage in Alzheimer's disease (AD) progression, which often coincides with the disruption of neural circuits and cognitive decline. While the role of excitatory-inhibitory balance is increasingly recognized in AD pathophysiology, targeted therapies to modulate this balance remain underexplored. This study investigates the effect of perampanel, a selective non-competitive AMPA receptor antagonist, in modulating neurophysiological changes in hAPP-J20 transgenic Alzheimer's mice.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Actinogen Medical, Sydney, Australia.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.

View Article and Find Full Text PDF

Background: Epidemiological studies report an elevated risk of neurodegenerative disorders, particularly Parkinson's disease (PD), in patients with type 2 diabetes mellitus (T2DM) that is mitigated in those prescribed incretin mimetics or dipeptidyl peptidase 4 inhibitors (DPP-4Is). Incretin mimetic repurposing appears promising in human PD and Alzheimer's disease (AD) clinical trials. DPP-4Is are yet to be evaluated in PD or AD human studies.

View Article and Find Full Text PDF

Background: Cilostazol, a selective type-3 phosphodiesterase inhibitor, ameliorates β-amyloid accumulation by facilitating intramural periarterial drainage.

Method: Patients with mild cognitive impairment were registered in the COMCID study, an investigator-initiated, double-blinded, multi-center, phase-II clinical trial. The primary endpoint was the Mini-Mental State Examination score.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!